

Anete Curte Ferraz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6621325/anete-curte-ferraz-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28 papers	1,157 citations	20 h-index	28 g-index
28 ext. papers	1,299 ext. citations	4 avg, IF	3.62 L-index

#	Paper	IF	Citations
28	A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. <i>Brain Research Protocols</i> , 2005 , 16, 58-64		144
27	Depression in Parkinsons disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. <i>Journal of Affective Disorders</i> , 2008 , 111, 351-9	6.6	133
26	Chronic Ω fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol. <i>Behavioural Brain Research</i> , 2011 , 219, 116-22	3.4	130
25	17 β -estradiol replacement in young, adult and middle-aged female ovariectomized rats promotes improvement of spatial reference memory and an antidepressant effect and alters monoamines and BDNF levels in memory- and depression-related brain areas. <i>Behavioural Brain Research</i> , 2012 , 227, 100-8	3.4	98
24	The role of 5-HT $_A$ receptors in fish oil-mediated increased BDNF expression in the rat hippocampus and cortex: a possible antidepressant mechanism. <i>Neuropharmacology</i> , 2012 , 62, 184-91	5.5	89
23	Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinsons disease. <i>Neuroscience Research</i> , 2010 , 66, 256-64	2.9	46
22	Motor and non-motor features of Parkinsons disease - a review of clinical and experimental studies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012 , 11, 439-49	2.6	45
21	Does Parkinsons disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 418-28	2.6	42
20	Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes. <i>Molecular Neurobiology</i> , 2016 , 53, 6997-7009	6.2	41
19	ER Stress Induced by Tunicamycin Triggers β -synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinsons Disease. <i>Molecular Neurobiology</i> , 2017 , 54, 5798-5806	6.2	41
18	Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats. <i>European Journal of Neuroscience</i> , 2014 , 39, 266-74	3.5	38
17	The antidepressant role of dietary long-chain polyunsaturated n-3 fatty acids in two phases in the developing brain. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2008 , 78, 183-8	2.8	35
16	Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinsons disease is mediated by a reduction of inducible nitric oxide synthase. <i>Nutritional Neuroscience</i> , 2018 , 21, 341-351	3.6	34
15	REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinsons disease. <i>Journal of Neuroscience Research</i> , 2013 , 91, 1508-16	4.4	30
14	Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. <i>Brain Research</i> , 2003 , 986, 200-5	3.7	30
13	Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. <i>Neurochemical Research</i> , 2008 , 33, 1238-46	4.6	27
12	Maternal Omega-3 Supplement Improves Dopaminergic System in Pre- and Postnatal Inflammation-Induced Neurotoxicity in Parkinsons Disease Model. <i>Molecular Neurobiology</i> , 2017 , 54, 2090-2106	6.2	24

11	Differential vulnerability of substantia nigra and corpus striatum to oxidative insult induced by reduced dietary levels of essential fatty acids. <i>Frontiers in Human Neuroscience</i> , 2012 , 6, 249	3.3	22
10	REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy. <i>Molecular Neurobiology</i> , 2015 , 51, 349-60	6.2	20
9	Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012 , 11, 359-68	2.6	20
8	Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation. <i>Neuropharmacology</i> , 2014 , 76 Pt A, 118-26	5.5	16
7	Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease. <i>Neurochemical Research</i> , 2011 , 36, 955-61	4.6	16
6	The Antidepressant-Like Effect of Fish Oil: Possible Role of Ventral Hippocampal 5-HT1A Post-synaptic Receptor. <i>Molecular Neurobiology</i> , 2015 , 52, 206-15	6.2	14
5	Fish oil has beneficial effects on behavior impairment and oxidative stress in rats subjected to a hepatic encephalopathy model. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013 , 12, 84-93	2.6	7
4	Fish-oil supplementation decreases Indoleamine-2,3-Dioxygenase expression and increases hippocampal serotonin levels in the LPS depression model. <i>Behavioural Brain Research</i> , 2020 , 390, 112675	3.4	6
3	Fish oil supplementation reverses behavioral and neurochemical alterations induced by swimming exercise in rats. <i>Physiology and Behavior</i> , 2018 , 194, 95-102	3.5	5
2	Multiple intranigral unilateral LPS infusion protocol generates a persistent cognitive impairment without cumulative dopaminergic impairment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013 , 12, 1002-10	2.6	4
1	Effects of Omega-3 on Neurodegenerative Diseases and Stroke 2015 , 187-201		